Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Scinai Immunotherapeutics ( (SCNI) ) just unveiled an announcement.
On March 2, 2026, Scinai Immunotherapeutics announced it had signed a second amendment to its binding option agreement to acquire Italian biotech PinCell S.r.l. and submitted a revised application under the European Funds for the Modern Economy SMART Path program. The amendment extends the deadline to fulfill option conditions to August 31, 2026, and the option exercise period to September 30, 2026, aligning the acquisition timeline with the expected three- to four-month evaluation of the grant request.
The updated application seeks €12 million in non-dilutive, non-repayable funding to co-finance 80% of a €15 million R&D program for PC111, a fully human monoclonal antibody targeting soluble Fas Ligand for pemphigus vulgaris and the severe orphan condition Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis. By restructuring the project into a milestone-driven path through integrated non-clinical and first-in-human data, Scinai aims to boost its competitiveness for the grant, potentially advancing PC111 to human proof of concept while preserving balance sheet flexibility and limiting shareholder dilution.
The most recent analyst rating on (SCNI) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Scinai Immunotherapeutics stock, see the SCNI Stock Forecast page.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
The score is held back primarily by weak financial performance—persistent operating losses and continued cash burn despite recent balance sheet improvement. Technicals are a moderate positive with the stock trading above key short-term averages and mildly positive momentum, while valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a Nasdaq-listed biopharmaceutical company that operates both as a contract development and manufacturing organization (CDMO) and as an immunology-focused drug developer. Its CDMO unit offers fee-for-service development and manufacturing for early-stage biologics and small molecules, while its internal pipeline includes the autoimmune candidate PC111 and next-generation NanoAb-based programs pursued via partnerships and licensing deals.
Average Trading Volume: 46,442
Technical Sentiment Signal: Sell
Current Market Cap: $603.6K
Learn more about SCNI stock on TipRanks’ Stock Analysis page.